Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation

被引:23
作者
Camacho, R
Staruch, MJ
DaSilva, C
Koprak, S
Sewell, T
Salituro, G
Dumont, FJ
机构
[1] Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Nat Prod Discovery, Rahway, NJ 07065 USA
来源
IMMUNOPHARMACOLOGY | 1999年 / 44卷 / 03期
关键词
immunosuppressant; T cell activation; IL-2; production; cytokine regulation; hypothemycin;
D O I
10.1016/S0162-3109(99)00085-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hypothemycin, a resorcylic acid lactone antibiotic, was identified as active in a screen for inhibitors of T cell activation. It was found to inhibit the proliferation of mouse and human T cells stimulated with anti-CD3 mAb + PMA and of human PBMC stimulated with anti-CD3 mAb alone. This inhibition was partially reversed by exogenous IL-2 indicating that it is not due to non-specific toxicity. Hypothemycin potently suppressed the production of IL-2 (IC50: 9 nM) but affected IL-2-induced proliferation to a lesser extent (IC50: 194 nM). Hypothemycin also inhibited IL-6, IL-10, IFN-gamma and TNF-alpha production. By contrast, it markedly enhanced the production of IL-4, IL-5 and IL-13. These effects were seen both at the mRNA and protein secretion levels. Analysis of the effect of hypothemycin on CD69 induction suggested that it disrupts calcineurin-independent rather than calcineurin-dependent signaling. Furthermore, hypothemycin was able to inhibit the phosphorylation of ERK1/2 induced by PMA treatment of T cells. Therefore, hypothemycin represents an inhibitor of T cell activation with a novel mode of action and unique modulatory activity on cytokine production. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 26 条
[1]  
AGATSUMA T, 1993, CHEM PHARM BULL, V41, P373, DOI 10.1248/cpb.41.373
[2]   Differential signaling by lymphocyte antigen receptors [J].
AlberolaIla, J ;
Takaki, S ;
Kerner, JD ;
Perlmutter, RM .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :125-154
[3]   T cell antigen receptor signal transduction pathways [J].
Cantrell, D .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :259-274
[4]  
Castellanos MD, 1997, J IMMUNOL, V159, P5463
[5]   Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways [J].
DeSilva, DR ;
Feeser, WS ;
Tancula, EJ ;
Scherle, PA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) :2017-2023
[6]   Defective T cell differentiation in the absence of Jnk1 [J].
Dong, C ;
Yang, DD ;
Wysk, M ;
Whitmarsh, AJ ;
Davis, RJ ;
Flavell, RA .
SCIENCE, 1998, 282 (5396) :2092-2095
[7]   A SYNTHETIC INHIBITOR OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE [J].
DUDLEY, DT ;
PANG, L ;
DECKER, SJ ;
BRIDGES, AJ ;
SALTIEL, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7686-7689
[8]  
Dumont F, 1996, PRINCIPLES DRUG DEV, P175
[9]  
Dumont FJ, 1998, J IMMUNOL, V160, P2579
[10]   RISK ASSESSMENT OF THE MYCOTOXIN ZEARALENONE [J].
KUIPERGOODMAN, T ;
SCOTT, PM ;
WATANABE, H .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1987, 7 (03) :253-306